Scientists Gene-Hack Spider to Produce Bright-Red Silk
Researchers used the popular gene-editing technique CRISPR to modify the DNA sequences of house spiders, causing them to produce red fluorescent silk.
Scientists are hoping that the US Navy and Air Force-funded research could lead to the development of new "supermaterials" produced by arachnids, Fast Company reports.
As detailed in a paper published in the journal Angewandte Chemie, a team of researchers at the University of Bayreuth in Germany injected the eggs of unfertilized female spiders with a CRISPR-Cas9 solution to insert a gene sequence for a red fluorescent protein. After mating with males of the same species, the offspring produced red, fluorescent silk, demonstrating that the experiment had been successful.
"Considering the wide range of possible applications, it is surprising that there have been no studies to date using CRISPR-Cas9 in spiders," said senior author and University of Bayreuth professor Thomas Scheibel in a statement. "We have demonstrated, for the first time worldwide, that CRISPR-Cas9 can be used to incorporate a desired sequence into spider silk proteins, thereby enabling the functionalisation of these silk fibres."
Apart from turning their silk bright red, the researchers also attempted to knock out a gene called sine oculis, which is responsible for the development of spider eyes. They found that the gene edit caused total or partial eye loss in experiments, highlighting its important role in visual development.
By applying CRISPR-Cas9, a technique that has already been widely used to create custom medical treatments or make farm animals more resilient to diseases, the researchers are hoping to come up with a new generation of silk fibers.
"Successful spider silk engineering in vivo will, therefore, help to develop and employ new fiber functionalities for a broad range of applications," the team wrote in its paper. "So far, genetic modifications in spiders have been only aimed at evolutionary and developmental research."
As Fast Company points out, materials scientists have already been investigating the tactile strength of the silk produced by gene-modified silkworms. But thanks to cutting-edge gene-editing techniques, researchers could soon harness the unique advantages of spider silk as well.
While the researchers didn't single out specific use cases for future "supermaterials," the possible applications are practically endless, from lightweight body armor to ultralight running shoes.
"The ability to apply CRISPR gene-editing to spider silk is very promising for materials science research — for example, it could be used to further increase the already high tensile strength of spider silk," Scheibel explained.
More on CRISPR: In a World First, CRISPR Drug Tailored for One Baby Shows Life-Saving Promise
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Epigenetics Market Anticipated to Achieve 11.8% CAGR
"Epigenetic Research Gains Momentum: Comprehensive Market Analysis Highlights Growing Clinical Relevance Across Various Diseases, Limited Clinical Applications in Oncology and Significant Market Potential Attracting New Entrants and Major Enterprises to the Epigenetics Products Market, Including Research Tools, Epigenetic Biomarker-Based IVDs and Targeted Therapeutics." Boston, June 03, 2025 (GLOBE NEWSWIRE) -- According to the latest study from BCC Research, the 'Global Epigenetics Markets' is projected to grow from $4.8 billion in 2024 to $8.5 billion by the end of 2029 at a compound annual growth rate (CAGR) of 11.8% from 2024 through 2029. The report offers quantitative and qualitative insights to help readers develop growth strategies, assess the market landscape and make informed business decisions. It covers various therapeutic classes, such as DNMT inhibitors, HDAC inhibitors, IDH inhibitors and EZH2 inhibitors. The report is segmented by study methods, clinical indications and drug classes. Additionally, it discusses industry growth drivers, restraints, trends, opportunities, competitive landscape and emerging technologies impacting the epigenetics market. The factors driving the market's growth include: Rising Cancer Rates: The increasing prevalence of cancer creates a demand for new treatments and diagnostic tools, driving epigenetic research to develop targeted therapies. Technological Advances: Innovations in tools like CRISPR and next-generation sequencing enhance our ability to study and manipulate epigenetic modifications, leading to better disease understanding and treatment. Increased Research Funding: More investment in biomedical research supports the development of new technologies and therapies, fostering innovation in epigenetics. Precision Medicine: The trend toward personalized treatments based on genetic profiles boosts the importance of epigenetics in developing effective, individualized therapies. Interest in Liquid Biopsy: Liquid biopsies offer a noninvasive way to detect and monitor diseases, and technological improvements are increasing their clinical adoption. Request a sample copy of the global market for epigenetics research tools and reagents, IVDs and therapeutics reports. Report Synopsis Report Metric Details Base year considered 2023 Forecast period considered 2024-2029 Base year market size $4.4 billion Market size forecast $8.5 billion Growth rate CAGR of 11.8% from 2024 to 2029 Segments covered Product type, study method, clinical indication, drug class and region Regions covered North America, Europe, Asia-Pacific and the Rest of the World (RoW) Market drivers The rising prevalence of cancer and unmet need in oncology. Advances in analytical technologies and tools. Increasing investment in biomedical research. The trend toward precision medicine. Growing interest in liquid biopsy. Interesting facts: Epigenetic drugs have been more clinically successful in hematological malignancies than solid tumors. Many companies are developing epigenetic biomarker-based blood tests for early cancer detection. Multicancer detection is a significant area of interest. Most epigenetic drugs in clinical trials and on the market are primarily focused on oncology areas, particularly hematological malignancies. Emerging startups: Helio Genomics: The company is developing a blood test for early cancer detection. Biomea Fusion Inc.: A clinical-stage biopharmaceutical company focused on the discovery and development of oral covalent small molecules to treat patients with metabolic disease and genetically defined cancers. The report addresses the following questions: What is the projected market size and growth rate of the epigenetics research tools, reagents, IVDs and therapeutics market? The global epigenetics market was estimated to be around $4.4 billion in 2023. It is projected to reach $8.5 billion in 2029, growing at a CAGR of 11.8% during the forecast period. What market segments are covered in the report? An in-depth analysis of the global epigenetics research tools, reagents, IVDs and therapeutics market, including historical data and market projection on sales by product type, study method, clinical indication, drug class and region. Which type segment will dominate the market by the end of 2029? The IVD type segment is anticipated to dominate the market by the end of 2029. Which market is growing fastest among all? The IVD segment is the fastest growing market. Leading companies in the market include: ACTIVE MOTIF INC. BIO-RAD LABORATORIES INC. BIO-TECHNE BRISTOL-MYERS SQUIBB CO. DAIICHI SANKYO CO., LTD. EXACT SCIENCES CORP. GUARDANT HEALTH HOLOGIC INC. LES LABORATOIRES SERVIER MERCK KGAA NUCLEIX PROMEGA CORP. QIAGEN REVVITY INC. (PERKINELMER) THERMO FISHER SCIENTIFIC INC. Related reports Include: Liquid Biopsy Research Tools, Services and Diagnostics: Global Markets: This report examines the industry structure, competitive landscape and profiles of leading companies, including their products, financials and recent activities. It also evaluates business strategies in the competitive environment and segments the market by application, analysis purpose, biomarker type and platform. Regional analysis spans North America, Europe, Asia-Pacific and the Rest of the world. Global DNA Sequencing: Research, Applied and Clinical Markets: The report on DNA sequencing explores its current and future market potential, analyzing drivers, restraints and opportunities. The market is segmented by technology (NGS, TGS, pyrosequencing and Sanger sequencing), product and service, end user, application, disease category and region. Key regions covered are North America, Europe, Asia-Pacific and the Rest of the World. Navigate Uncertainty with ConfidenceIn times of rapid change and uncertainty, having the right insights can make all the difference. At BCC Research, we are here to support innovation and help you stay ahead. Our custom research reports provide a comprehensive, 360-degree view of your market landscape, giving you the clarity you need to make informed decisions. We believe that timely, expert market intelligence should be accessible to all. That is why, for a limited time, we're offering 30% off the price of any BCC Research report to help more organizations gain access to our latest data and insights. Purchase a copy of the report directly from BCC Research. For further information on any of these reports or to make a purchase, contact info@ About BCC Research BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype. For media inquiries, email press@ or visit our media page for access to our market research library. Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. CONTACT: BCC Research Corporate HQ: 50 Milk St., Ste. 16, Boston, MA 02109, USA Email: info@ Phone: +1 781-489-7301


Associated Press
6 hours ago
- Associated Press
Gene Editing Market Research 2025-2029 by Application, Technology, Place, Industry and Product with Executive & Consultant Guides
DUBLIN--(BUSINESS WIRE)--Jun 3, 2025-- The 'Gene Editing Markets 2025-2029 by Application, Technology, Place, Industry and Product with Executive & Consultant Guides' report has been added to offering. This comprehensive view of the gene editing landscape highlights the technology's potential to drive transformative change. As breakthroughs become more frequent, businesses need to stay informed about the latest trends and projections. Those equipped with thorough market insights are poised to leverage these technologies effectively, ensuring competitive advantages in their respective fields. Gene Editing is moving from strength to strength. CRISPR and similar tools are finding new uses in every area of biotechnology. It started with Medical applications by changing genes in living human cells. Uncurable diseases have already being cured. More are on the way. The market for gene editing tools is witnessing a surge, with rapid growth driven by technological advances. These tools are broadening their reach beyond healthcare, offering groundbreaking possibilities in agriculture, biofuel production, and more. Major players in the biotechnology industry are spearheading research to develop innovative applications, ensuring continual market evolution. Industry experts indicate that the gene editing industry is set to continue its rapid expansion. Companies and researchers are actively investigating diverse opportunities in areas such as crop improvement, pest control, and sustainable resource management. These developments position gene editing as a cornerstone technology, promising significant impacts on global food security and sustainable practices. The gene editing market is becoming increasingly sophisticated, with new applications and technologies emerging regularly. As demand for more precise and efficient biotechnological solutions grows, the sector continues to attract substantial investment. Key players are focusing on research and development, strengthening their market positions, and pushing forward innovations to meet both current needs and future challenges. Key Topics Covered: 1 Market Guides 1.1 Strategic Situation Analysis 1.2 Guide for Executives, Marketing, Sales and Business Development Staff 1.3 Guide for Management Consultants and Investment Advisors 2 Introduction and Market Definition 2.1 Methodology 2.1.1 Methodology 2.1.2 Sources 2.1.3 Authors 2.2 What is Gene Editing? 2.3 The CRISPR Example 2.3.1 What is CRISPR? 2.3.2 The CRISPR Family 2.4 Chromosomes, Genes and Epigenetics 2.4.1 Chromosomes 2.4.2 Genes 2.4.3 Epigenetics 2.5 Market Definition 2.5.1 Revenue Market Size 2.6 Perspective: Healthcare Spending 2.6.1 Global Healthcare Spending 2.6.2 Spending on Healthcare and Pharmaceuticals 2.6.3 Spending on Diagnostics 2.6.4 Important Role of Insurance for Medical Services 3 Market Structure 3.1 Market Structure Therapeutics 3.1.1 Research and Development (R&D) Companies 3.1.2 Biotechnology Companies 3.1.3 Generic Drug Manufacturers 3.1.4 Big Pharmaceuticals 3.1.5 Contract Research Organizations (CROs) 3.1.6 Contract Manufacturing Organizations (CMOs) 3.1.7 Specialty Pharmaceutical Companies 3.1.8 Pharmaceutical Distributors 3.1.9 Retail Pharmacies 3.1.10 Wholesalers 3.1.11 Online Pharmacies 3.1.12 Health Technology Companies 3.1.13 Pharmacy Benefit Managers (PBMs) 3.1.14 Clinical Laboratories 3.1.15 Medical Device Companies 3.1.16 Regulatory Bodies 3.2 Market Structure Diagnostics 3.2.1 Academic Research Lab 3.2.2 Diagnostic Test Developer 3.2.3 Instrumentation Supplier 3.2.4 Chemical/Reagent Supplier 3.2.5 Pathology Supplier 3.2.6 Independent Clinical Laboratory 3.2.7 Public National/regional Laboratory 3.2.8 Hospital Laboratory 3.2.9 Physicians Office Lab (POLS) 3.2.10 Audit Body 3.2.11 Certification Body 4 Market Trends 4.1 Factors Driving Growth 4.1.1 Cell Therapy 4.1.2 Gene Therapy 4.1.3 The New Agriculture 4.1.4 Genetics and Cell Metabolism 4.2 Factors Limiting Growth 4.2.1 The Cost Curve 4.2.2 Time and Trials 4.2.3 The Price Barrier 5 Recent Developments in Gene Editing 5.1 Recent Developments - Importance and How to Use This Section 5.1.1 Importance of These Developments 5.1.2 How to Use This Section 5.2 CRISPR tool allows for remote-controlled gene-editing 5.3 CRISPR Making Sweeter Tomatoes 5.4 Researchers Create gene-edited prawns 5.5 Gene Editing Corrects Cystic Fibrosis 5.6 CRISPR gene editing to change healthcare? 5.7 CrisprBits Collaborates With MolBio Diagnostics 5.8 Sherlock Bioscience to Launch Free AI-Based Operating System 5.9 Sherlock Biosciences to Acquire Sense Biodetection 5.10 CRISPR Enzyme Discovery Opens New Applications 5.11 Sherlock Biosciences Adds Ambient Amplification to Toolkit 5.12 Rice University Adapts CRISPR Enzyme 5.13 Princeton Group Develops Cas13 Assay for Point-of-Care Use 5.14 Proof Dx Plans Infectious Disease, Oncology Tests for CRISPR-Based POC System 5.15 Sherlock Biosciences Raises $80M 5.16 Broad Institute Considers CRISPR Respiratory Panels to Replace PCR 5.17 Medix Biochemica Acquires MyPols Biotec 5.18 Mammoth Biosciences High-Throughput CRISPR-Based COVID Test Gets EUA 5.19 Genome Diagnostics Makes €1M Investment in Scope Biosciences 5.20 CRISPR Test Could be used for Asymptomatic Screening 5.21 Mammoth Biosciences, Agilent to Comarket CRISPR-Based SARS-CoV-2 Test 5.22 Pandemic Accelerates Development of CRISPR Diagnostics 5.23 ERS Genomics Licenses CRISPR Patents to Vivlion 5.24 Mammoth Bio Signs Commercialization Deal for SARS CoV-2 Test 5.25 ERS Genomics, FASMAC to Commercialize CRISPR-Cas9 5.26 The Nobel Prize in Chemistry 2020 - CRISPR Wins 6 Key Companies 6.1 10x Genomics, Inc. 6.2 4D Molecular Therapeutics 6.3 Abeona Therapeutics 6.4 Acrigen Biosciences 6.5 Adarx Pharmaceuticals 6.6 Adverum Biotechnologies 6.7 Affini-T Therapeutics 6.8 Agilent 6.9 Arbor Biotechnologies 6.10 Arcturus Therapeutics 6.11 Axxam 6.12 Beam Therapeutics 6.13 Beckman Coulter Diagnostics (Danaher) 6.14 Becton, Dickinson and Company 6.15 Binx Health 6.16 bioMerieux Diagnostics 6.17 Bio-Rad Laboratories, Inc. 6.18 Bluebird Bio 6.19 Caribou Biosciences 6.20 Cell Microsystems 6.21 Cellenion (BICO) 6.22 Century Therapeutics 6.23 Chroma Medicine 6.24 Creative Biogene 6.25 Crispr Therapeutics 6.26 Editas Medicine 6.27 ERS Genomics 6.28 FASMAC 6.29 Genscript Biotech 6.30 Illumina 6.31 Inscripta 6.32 Intellia Therapeutics 6.33 J&J Innovative Medicine 6.34 Locus Biosciences 6.35 Mammoth Biosciences 6.36 Metagenomi 6.37 Myllia Biotechnology 6.38 Namocell 6.39 NRGene 6.40 Poseida Therapeutics 6.41 Precision Biosciences 6.42 Prime Medicine 6.43 Proof Diagnostics 6.44 Regeneron Pharmaceuticals 6.45 Revvity 6.46 Roche Diagnostics 6.47 Sherlock Biosciences 6.48 Thermo Fisher Scientific 6.49 Twist Bioscience 6.50 Verve Therapeutics 6.51 Vivlion 6.52 Wave Life Science 7 The Global Market for Gene Editing 7.1 Global Market Overview by Country 7.2 Global Market by Application - Overview 7.3 Global Market Technology - Overview 7.4 Global Market Type - Overview 7.5 Global Market Industry - Overview 7.6 Global Market Product - Overview 8 Gene Editing Markets - By Application 8.1 Cell Line 8.2 Plant 8.3 Animal 8.4 Cell Therapy 8.5 Gene Therapy 8.6 Diagnostics 8.7 Research 9 Global Gene Editing Markets - by Technology 9.1 Crispr 9.2 Talens 9.3 ZFN 9.4 Meganuclease 10 Gene Editing Markets - by Place 10.1 In Vivo 10.2 Ex Vivo 10.3 In Vitro 11 Gene Editing Markets - by Industry 11.1 Pharma 11.2 Clinical 11.3 Academic 11.4 Contract 12 Global Gene Editing Markets - by Product 12.1 Instruments 12.2 Cells 12.3 Reagents 13 Appendices 13.1 United States Medicare System: laboratory Fees Schedule 13.2 The Most Used IVD Assays 13.3 The Highest Grossing Assays 13.4 The Whole Genome Sequence of SARS-CoV-2 13.5 Global Listing of Sequencing Establishments - Location & Contacts For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. View source version on CONTACT: Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 KEYWORD: INDUSTRY KEYWORD: HEALTH GENETICS SOURCE: Research and Markets Copyright Business Wire 2025. PUB: 06/03/2025 09:49 AM/DISC: 06/03/2025 09:47 AM


Fast Company
10 hours ago
- Fast Company
Elon Musk's Starship failed—again. We're all better for it
The latest attempt at space travel by billionaire Elon Musk's company SpaceX failed spectacularly once again last week. After the two previous attempts ended in explosions, last Tuesday's liftoff—the Starship's ninth in total—ended with it spinning uncontrollably about 30 minutes into the flight. The flight also failed to meet other objectives set for the mission, including the deployment of mock satellites into space. To anyone with an interest in space travel or astronomy in general, this is probably pretty disappointing news. Even Musk's self-proclaimed fanboys are feeling let down after yet another unsuccessful flight. But it's my opinion that this latest technological failure is a blessing in disguise. Of course, humans have accomplished space travel in the past. But as Musk described in a speech last week, he has a specific ambition: the colonization of Mars. Despite the fact that no human has yet set foot on Mars, let alone figured out how to make its environment habitable for humans, Musk is determined to make life on Mars possible. This is where the Starship, specifically, factors in: The rocket is the largest ever built, and Musk intends to use it to send an uncrewed mission to Mars by the end of 2026; the eventual goal is to transport private citizens—'hundreds of thousands if not millions' of them—to Mars. He believes that humanity not only can but should secure its future by going to 'the asteroid belt, the moons of Jupiter . . . and other star systems . . . making science fiction no longer fiction.' advertisement The extended deadline for Fast Company's Brands That Matter Awards is this Friday, June 6, at 11:59 p.m. PT. Apply today.